Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Asian study of vorasidenib in residual or recurrent IDH1/2-mutant grade 2 glioma
CTR20242581Phase 3Active
- Sponsor
- Servier
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vorasidenib in glioma, Oligodendroglioma (OG), astrocytoma, sponsored by Servier. Started Oct 2024; status: active.
02
Drugs
vorasidenib
03
Conditions
gliomaOligodendroglioma (OG)astrocytoma
Beyond the preview
Go deeper on CTR20242581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242581.